Search This Blog

Friday, August 5, 2022

Neurocrine Biosciences Shares Jump After Raising Ingrezza Sales Guidance

 

  • Tucked in its Q2 earning releaseNeurocrine Biosciences Inc  said that in August, the Phase 2a study of NBI-827104 in essential tremor did not meet specified endpoints. 
  • Based on the totality of data from the Phase 2a study, at this time, the company will not proceed further with the clinical development of NBI-827104 in essential tremors.
  • The FDA has signed off Neurocrine's Investigational New Drug (IND) Application for a Phase 2 trial of NBI-1117568 for schizophrenia.
  • The achievement triggers a $30 million payment to Neurocrine's partner Sosei Heptares.
  • NBI-1117568 is an oral, selective muscarinic M4 receptor agonist in development for treating schizophrenia and other neuropsychiatric disorders.
  • Clinical studies completed to date have shown NBI-1117568 to be generally well tolerated.
  • Q2 sales increased 31% Y/Y to $378.2 million, and Ingrezza product sales were $350 million, with total prescriptions of approximately 64,200.
  • Net product sales and TRx grew 32% and 31%, respectively, vs. the second quarter of 2021.
  • The company raised the FY22 Ingrezza sales outlook to $1.35 billion - $1.4 billion, higher than the $1.25 billion - $1.35 billion expected earlier.

Hospitals Will Still Have to Share Safety Data Publicly

 Patient safety advocates and organizations representing large purchasers of employee health plans rejoiced this week after CMS reversed its proposal in May to suppress a composite score of key hospital safety metrics.

The composite score, called the PSI 90, includes the rates of 10 preventable and potentially lethal in-hospital harms such as pressure ulcers, falls resulting in a hip fracture, postoperative respiratory failure, and postoperative sepsis.

In its proposed rule issued in May, CMS argued that hospitals were struggling with multiple pressures such as staffing shortages during COVID-19, and should get a break from being held accountable for their performance on these measures while they were under such duress.

But representatives of consumer organizations including Bill Kramer, executive director for health policy for the Purchaser Business Group on Health and Leah Binder of the Leapfrog Group, which uses the data for its hospital quality of care scorecards, fought back.

"Patients will be unable to know whether the provider they want to go to has more patient safety problems, more risky providers, so clinicians as well as purchasers and policymakers will be unable to identify and help patients choose those hospitals with the best patient safety record," Kramer said when the rule was proposed. Without that information, patients are more likely to suffer from avoidable accidents, "and some of them will die as a result."

CMS reconsidered, acknowledging in its final Inpatient Prospective Payment System rule on August 1 that it would not go ahead with its proposed rule to suppress the PSI 90 composite scores. The agency said it found a way to publicly report the PSI 90 data by combining two pre-COVID quarters in 2019 and two quarters during the COVID public health emergency in 2021. In doing so, it plans to exclude from those datasets patients with a COVID diagnosis.

"Since the publication of the proposed rule, we have been able to determine a method for excluding patients with a diagnosis of COVID-19 that will allow us to calculate and publicly report valid and reliable measure results," the agency wrote in its final rule. "Therefore, based on this measure adjustment and stakeholder support for continued public reporting, we are not finalizing our proposal to suppress the calculating and public reporting of CMS PSI 90 measure results for the FY 2023."

The agency added that these adjustments provide "an important step in providing transparency and upholding quality of care and safety for consumers."

In responding to the news that CMS had changed its mind, Missy Danforth, Leapfrog group's vice president for healthcare ratings, said that now, there won't be "this huge black hole in publicly available data for these really serious medical and surgical complications until sometime in 2024."

Likewise, Kramer told MedPage Today in an email that public reporting of PSI 90 will allow consumers and purchasers to compare hospitals' rates of "preventable errors that kill 25,000 hospitalized patients each year," enabling patients and their families to see which hospitals had practices and precautions that avoided such medical errors, even during the COVID public health emergency.

"These high performers should be seen as models of excellence for other hospitals as they strive to ensure quality in future pandemics and similar stresses," Kramer wrote.

PSI 90 is part of the Hospital Acquired Condition Reduction program, a scoring system in which CMS usually imposes a 1% Medicare pay cut on hospitals in the worst performing 25%, in that they had the most preventable adverse events.

However, in its final rule, CMS determined that because of the difficulties hospitals endured during the COVID public health emergency, it "would not be able to score hospitals fairly" in a way that would affect their revenue, so CMS is not imposing the financial penalty for the 2023 fiscal year.

Binder said in an interview with MedPage Today that the Leapfrog Group prefers that CMS would maintain the HAC reduction penalty, which was established by the Affordable Care Act, and impose financial penalties against the hospitals that had the worst scores as the agency has done since the program took effect in 2014. According to CMS, penalizing those hospitals would avoid reimbursing them some $350 million of taxpayer funds for the fiscal year.

"However, we do understand that there are political issues and sensitivities right now for CMS in penalizing hospitals financially for anything" as they recover from the hardships of operations during the pandemic.

For Binder and Leapfrog, "the most important thing for all of us is transparency. And that's something that CMS has made a firm foundation in this final rule. They are really committed to putting a priority on patient safety, and we credit them for that."

In a press statement, the American Hospital Association said it was pleased with the agency's decision not to penalize hospitals under the Hospital Acquired Condition (HAC) Reduction Program as well as the Value Based Purchasing Program, which can mean up to a 2% reduction in payment for poorly scoring hospitals.

"However," the AHA statement said, "we are concerned that CMS' decision to publicly report pandemic-distorted data from the HAC Reduction Program's patient safety indicator could mislead the public and fail to advance patient safety."

https://www.medpagetoday.com/special-reports/features/100063

Alzheimer's Blood Tests: Not Ready for Primary Care

 Blood biomarkers may change how Alzheimer's disease is diagnosed but aren't ready for widespread use in primary care yet, a panel of experts said.

"The field of blood-based biomarkers is moving very, very fast," said Oskar Hansson, MD, PhD, of Lund University in Malmö, Sweden, who presented the Alzheimer's Association's appropriate use recommendations for blood biomarkers at the 2022 Alzheimer's Association International Conference.

The recommendations, published in Alzheimer's & Dementia, are not appropriate use criteria, Hansson noted. "It's likely we will need to update these recommendations within 12 months."

The Alzheimer's Association working group of clinicians and researchers did not recommend blood-based biomarkers for population risk screening or as direct-to-consumer tests at this time.

"However, blood-based biomarkers are very likely to revolutionize the diagnosis of Alzheimer's in the future," Hansson said.

In the report, the group recognized a significant unmet need for better diagnostic tools, noting that 25% to 30% of people who receive a clinical diagnosis of Alzheimer's are misdiagnosed.

"Misdiagnosis of Alzheimer's is far too common," said Maria Carrillo, PhD, chief science officer of the Alzheimer's Association.

"Blood-based markers show promise for improving the diagnostic work-up for Alzheimer's, but additional data are needed before they can be used as a stand-alone test for diagnosis, and before considering broad use in primary care settings," she added.

The group provided recommendations for plasma amyloid-beta 42/amyloid-beta 40 (Aβ42/Aβ40), phospho-tau (p-tau), neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and potential combinations of markers.

Some of these biomarkers, especially Aβ42/Aβ40 and p-tau, are changing how clinical trials are designed, Hansson noted.

But even in clinical trials, caution is warranted, he pointed out. Blood biomarkers can be used as exploratory outcomes, but should not yet be used as primary endpoints in pivotal treatment trials. They also may help inform decisions about whether some clinical trials should be continued or help identify patients who may have Alzheimer's-related brain pathology in non-Alzheimer's trials.

The group also identified what research is needed to fill knowledge gaps, including how well blood markers work in diverse populations and in people with multiple health conditions. In addition, no studies have evaluated blood-based biomarkers for neurodegenerative diseases in primary care extensively. How these biomarkers may influence diagnostic accuracy and patient management also is unknown.

The Alzheimer's Association workgroup called for:

  • Prospective studies in primary care settings, including representative and diverse populations with cognitive symptoms.
  • Analyses to determine whether blood biomarkers outperform what is already available in primary care and whether they improve diagnosis and management.
  • Better understanding of biological and disease-associated variability and the potential effects of medical comorbidities and concomitant medications on dementia
  • An assessment of whether blood biomarker algorithms can be used alone to support an Alzheimer's diagnosis or whether additional cerebrospinal fluid (CSF) and PET studies are needed.

"We also recommend cautiously starting use of blood-based biomarkers in specialized memory clinics as part of the diagnostic work-up of patients already experiencing cognitive symptoms, as long as the results are confirmed whenever possible with CSF or PET, which are the current reference standards," said workgroup member Charlotte Teunissen, MD, PhD, of Amsterdam University Medical Center in the Netherlands.

Blood-based biomarkers in primary care will take longer to implement due to limited research to date, but prospective studies are launching soon, she added.


Disclosures

Hansson disclosed institutional research support from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has also received consultancy/speaker fees from Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Fujirebio, Genentech, Novartis, Roche, and Siemens.

Teunissen has a collaboration contract with ADx Neurosciences, Quanterix, and Eli Lilly, and has performed contract research or received grants from AC-Immune, Axon Neurosciences, Biogen, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, PeopleBio, Roche, Toyama, and Vivoryon.

Carrillo is a full-time employee of the Alzheimer's Association.

Is the Travel Nurse Pay Boom Really Over?

 As the travel nursing boom -- fueled by demand during the pandemic and a nationwide nurse shortage -- begins to show signs of fading, some experts believe the overall outlook for travel nurse wages will remain strong, even amid uncertainty in the healthcare labor market.

Last week, executives at HCA Healthcare said during an analyst call that they expected a decrease in "contract labor" in the near future, and that company expenses for temporary staffing were down 22% from April to June, the Wall Street Journal reported.

Travel nurses reportedly earned as much as $10,000 a week during the height of the pandemic, according to the WSJ article, which described a distorted market for nurse wages as the result of the collision of pandemic-related demand for staffing with existing staff shortages.

While staff shortages have persisted and wages have remained higher for nurses in both contract and permanent positions, some industry leaders are expecting a downturn in the wages and contracts for traveling nurses, the article stated.

But not all experts believe in the negative outlook. Patricia Pittman PhD, of the Milken Institute School of Public Health at George Washington University, told MedPage Today via email that even during the height of the pandemic, the total number of travel nurses was not at an all-time high.

"It's possible that hospital executives' outcry about travel industry pricing was overblown," Pittman told MedPage Today. "They are not always the best sources about what is actually happening on the ground, because they have a vested interest in constructing certain stories."

She does see some trends toward a more moderate market for travel nurses though. For one, she noted, some hospitals are taking action to avoid hiring more contract nurses. For example, some hospitals are try to retain permanent staff by offering more pay increases and bonuses, or they are developing internal "float nurse pools" to act as in-house travel nurses.

Pittman also thinks any suggestion that the boom is over might merely be a reflection of cyclical staffing needs. Hospital groups might have less of a need for travel nurses at the moment, which allows them to temporarily reduce spending on those contracts. Pittman cautioned that such changes are usually based on the typical cycle of travel nursing.

In fact, a closer look inside the travel nursing world reveals a relatively stable situation. One registered nurse who has completed several inpatient travel contracts at hospitals in the Midwest and who asked to remain anonymous said she has seen no evidence that these contracts are being reduced.

She told MedPage Today that she's not sure how anyone can accurately predict what will happen with travel nursing. For example, her hospital announced at one point that they would be ending travel nursing contracts within 6 months, but that was 2 years ago and the number of contract nurses hasn't changed much.

"I don't believe these hospital systems that say that they can't afford these travelers, but then they keep employing them and make no meaningful plans to hire more permanent staff or don't do anything to incentivize permanent staff to stay," she told MedPage Today. "So it doesn't make any sense to me. It seems like somebody's run the numbers, and they actually can afford more travelers."

This experience was reflected in a recent survey of registered nurses reported by MedPage Today that showed there is still an increased need for nurses amid low staffing. That survey, which involved more than 9,000 nurses, found only 24% of respondents believed their units had enough nurses with the proper skill level most of the time. That result declined from 39% in a 2018 version of the survey.

In line with Pittman's expectation that current trends are cyclical, the short-term outlook for travel nursing pay appears set to decline as much as 15%, Brian Tanquilut, an analyst at Jefferies, told the WSJ. He noted that current weekly pay for travel nurses is just over $3,000. It's a sharp decline from the highest pay over the pandemic, but Tanquilut told WSJ that it likely would not drop to pre-pandemic rates.

Several stakeholders, including nursing organizations and staffing agencies, declined to comment for this article.

Pittman also noted that larger economic concerns loom over travel nursing and the country as a whole.

"If there is a recession coming -- and even if nurses and their families just think there is a recession coming -- we are likely to see some nurses returning to work," Pittman said. "This is the traditional counter cyclical nature of the nurse workforce."

https://www.medpagetoday.com/special-reports/exclusives/100076

COVID Patients May Be Infectious Beyond 5 Days

 A substantial proportion of COVID-19 patients who continue to test positive on a rapid antigen test after 5 days may still be infectious, according to a small study.

Of 17 patients who were tested for viral culture on day 6, 12 still had a positive antigen test, and six of these patients had culturable virus, a proxy for infectiousness, reported Lisa Cosimi, MD, of Brigham and Women's Hospital in Boston, and colleagues in JAMA Network Open.

These findings could have implications for current CDC guidelines that recommend ending isolation after 5 days if afebrile for 24 hours and symptoms are improving.

Cosimi said rapid antigen tests (RATs) correlate well with viral culture in the first several days of infection, so one might have expected the percentage of culturable samples to be higher. However, she noted, these tests haven't been validated for use in the later phases of infection, such as after day 5.

While previous studies have correlated antigen test positivity with culture positivity during early infection, there aren't much data on test positivity and culturable virus more than 5 days after infection, even though people can test positive for far longer.

"It's plausible that, similar to PCR testing, RATs are detecting viral shedding that is not actually capable of transmission," Cosimi told MedPage Today in an email. "Therefore, maintaining isolation through day 10 may unduly isolate a large number of individuals who are not still infectious."

"However, given these data, there is also a risk that individuals are leaving isolation while still infectious," she added. "We strongly agree with CDC's recommendation to wear a tight-fitting mask on days 6-10, especially if RAT positive, and to avoid areas where there is a high risk of transmission to others."

Cosimi and colleagues enrolled 40 people with COVID-19 (mean age 34) from January 5 to February 11, when Omicron BA.1 was the predominant strain in the Boston area. The majority of the participants (75%) had a positive rapid antigen test on day 6; only 10 participants had a negative test on day 6.

The researchers focused on a convenience sample of 17 individuals, collecting anterior nasal and oral swabs on day 6 to grow in culture, as culturable virus is currently the best proxy for transmissibility.

Of the six people who had culturable virus, two had improving symptoms, two had unchanged symptoms, and two never reported any symptoms.

None of the five people with a negative rapid antigen test on day 6 had positive cultures. In addition, seven of the nine people who had no symptoms on day 6 had negative culture results.

All patients in the study were negative by day 14, and the mean day of first negative rapid antigen test was 9.3 in those who'd ever had symptoms and 8.1 in those who'd never had symptoms.

Cosimi pointed to two other small studies that found culturable virus after day 5. One study found that 17% of vaccinated college students had culturable virus after day 5 from symptom onset, with the latest on day 12. Another found the median time to culture conversion to negative was 6 days after an initial diagnosis with a PCR test.

The researchers concluded that the data "suggest that a negative RAT result in individuals with residual symptoms could provide reassurance about ending isolation. However, a universal requirement of a negative RAT result may unduly extend isolation for those who are no longer infectious. Meanwhile, a recommendation to end isolation based solely on the presence of improving symptoms risks releasing culture-positive, potentially infectious individuals prematurely, underscoring the importance of proper mask wearing and avoidance of high-risk transmission venues through day 10."

The study was limited by its small cohort of mostly young, vaccinated, and non-hospitalized patients, and thus may not be generalizable to a wider population.


Disclosures

The authors reported financial relationships with Cell Signaling Technologies, Sherlock Biosciences, and Proof Diagnostics.

How Well Does the Monkeypox Vax Work? No One Knows for Sure

 Across an American gay male community worried about catching monkeypox, one message suggests this is all temporary: A few months of sexual caution plus vaccination will usher in a care-free autumn.

"For your own safety, and to spare you the horrors of this disease," sex columnist Dan Savage suggested on Twitter last weekend, "you might wanna think about maybe dialing it back for a few weeks while we roll the vaccine out." The AIDS magazine POZ recommends that readers "hold off on a slutty summer" and wait for the fall, when "we hope to have enough Jynneos vaccines for all who want it."

Yet no one knows how well the Jynneos vaccine will serve as a get-out-of-infection-free card.

One number that's been unquestionably quoted by various media organizations -- "85% effective" or "at least 85% effective" -- is based entirely on a small study done in Africa in the 1980s that has major limitations. One data expert calls its findings "pretty weak." Other studies have only been conducted in animals.

Still, "I've heard from many folks in the community that they expect almost no risk of becoming infected 2 weeks after their first shot," said Michael Donnelly, MSc, a New York City data scientist and LGBT health advocate, in an interview with MedPage Today. "Or they think they won't get any symptoms if they were exposed before their shot."

The lack of accurate information about the vaccine is "a big problem," Jay Varma, MD, director of the Cornell Center for Pandemic Prevention and Response in New York, said in an interview. "It is absolutely critical that public health officials work on messaging this uncertainty to people being vaccinated."

Vaccine Assumptions Based on Small, 'Weak' 1988 Study

As of July 29, the CDC reports that the current outbreak has caused 5,189 infections in the U.S., striking nearly every state (all except Montana, Wyoming, and Vermont) plus Puerto Rico. New York is by far the most affected with 1,345 cases, followed by California with 799, Illinois with 419, Florida with 373, and Texas and Georgia with 351 apiece. There's an especially high per-capita rate in Washington D.C., with 218 cases in a city of 702,000 people.

Men who have sex with men are considered most vulnerable -- they made up 98% of 528 worldwide cases in a recent analysis -- and many gay men have gone onto social media or spoken to reporters to describe intense pain, horrific lesions, and barriers to care.

Hundreds of thousands of Jynneos smallpox/monkeypox vaccines are now available in the U.S., and the CDC recommends vaccination for those who have been exposed to monkeypox or are at higher risk.

Health officials prefer the Jynneos vaccine, which is manufactured by the Danish company Bavarian Nordic and FDA-approved to prevent both smallpox and monkeypox. An alternative vaccine, ACAM2000, is complicated to administer, produces a nasty and infectious pustule, and can cause side effects in some people such as those with weakened immune systems, according to Vox.

As the CDC notes, "no data are available yet on the effectiveness of these vaccines in the current outbreak." As for previous outbreaks, only one study -- a retrospective analysis published in 1988 -- has examined whether a smallpox vaccine could prevent monkeypox.

In that study, researchers tracked the household contacts of 209 people infected with monkeypox in Zaire in the early 1980s. Those with scars from previous smallpox vaccination (70%) were 85% less likely to be infected. The vaccine seemed to be 89% effective at protecting contacts outside the household from infection.

The statistical analysis is limited since it has no confidence interval or adjustment for factors such as age, Ira Longini, PhD, a biostatistician at the University of Florida, told MedPage Today. Also, he said, the data are purely based on physical signs of vaccination. The study "is the only shred of evidence we have [in regard to vaccine effectiveness], which is pretty weak. In principle it should work, but we don't know."

Jynneos and ACAM2000 are newer generations of vaccines such as Dryvax that were used in the 1980s. "These vaccines have not been tested directly against smallpox or monkeypox," said Richard Kennedy, PhD, co-director of the Mayo Vaccine Research Group in Rochester, Minnesota, in an interview with MedPage Today. "The immune responses they create are very close to first- or second-generation vaccines: A little weaker, but not much."

Kennedy added that the vaccines also have been tested against monkeypox in five to 10 different animal studies. "These data are also clear and consistent with very good protection against disease with animals showing very few or no symptoms of illness after challenge," Kennedy said. "The animal data was strong enough that the FDA approved Jynneos to be licensed for prevention of monkeypox."

Unique Outbreak May Weaken Vaccine's Effects

To make matters more complicated, the new outbreak is quite different from those in the past. This time, the virus appears to largely be transmitted through sexual rather than other kinds of contact, with an overwhelming majority of cases among men who have sex with men. (There's now a debate in the medical world over whether to refer to monkeypox as a sexually transmitted disease [STD].) Previous outbreaks in Africa appeared to have been spread in households by various routes.

"The vaccine was evaluated on the assumption that most or all exposures would be from skin-to-skin contact," Varma told MedPage Today. "The head of the penis and interior of the anus may have characteristics that make them more susceptible to infection such as a lower dose of virus needed, less abundant antibodies or other components of the immune system, or concurrent STDs increasing risk. It's possible that the level of protection may be the same, but we should not assume it's the same without evaluating it."

Also, he said, "it is theoretically possible for a monkeypox virus to develop mutations that make it more contagious or virulent to humans. The scientific consensus is that this is less likely to happen as quickly as happens with COVID, given the type of virus. COVID is an RNA virus, and monkeypox is a DNA virus."

Kennedy agreed. "The current outbreak is caused by a strain that has a few genetic differences but is still very close to the strains causing monkeypox in the 1980s," he said. "This isn't like COVID-19 where you have a new strain with substantial immune evasion every few months. There is a lot of cross-protection with poxviruses -- an immune response to one poxvirus can recognize most other poxviruses."

Fine-Tuning a Monkeypox Prevention Message

Despite the weakness of the evidence, the 85% efficacy number is everywhere -- sometimes with qualifications, sometimes not. Even Yale University and Harvard University have published health alerts that quote the 85% figure without noting its uncertainty.

Meanwhile, monkeypox prevention messages aimed at gay and bisexual men continue to vary. Vaccinations are heavily touted along with other strategies as officials worry about stigmatizing gay men.

Last week, the head of the World Health Organization suggested "reducing your number of sexual partners, reconsidering considering sex with new partners, and exchanging contact details with any new partners to enable follow up if needed."

The CDC offered advice about having sex if someone may be infected: stay 6 feet apart during mutual masturbation and avoid kissing. And the magazine POZ suggests using condoms, wearing more clothes at circuit parties and bars, and creating sex "pods" similar to the groups of friends and relatives who only socialized with each other during the COVID-19 pandemic.

Suggestions about condoms may be especially challenging for men who have sex with men to accept. Many gay men prefer to reduce their risk of HIV transmission by taking preventive drugs like emtricitabine/tenofovir (Descovy, Truvada) or, if they are HIV-positive, by lowering their viral loads to undetectable levels via medication.

"The prevention messaging should be that vaccinations will be an essential part of getting this outbreak under control, and we need everyone to get vaccinated as soon as possible," said Donnelly, the data scientist and LGBT health advocate. "But even if you're vaccinated, you're still at risk, and unprotected anal sex may be the highest risk."

"Even after vaccination," he added, "you may want to consider reducing the number of your sex partners and using condoms or pursuing other safer sex approaches."

https://www.medpagetoday.com/special-reports/exclusives/100010

NY Samples Show Polio Virus in Different County as State Warns of Community Spread

 

  • More polio has been detected in Hudson Valley wastewater samples, this time Orange County, according to NYS health officials, which it says further indicates potential community spread of the virus declared eradicated in 1979
  • The CDC detected polio in samples taken from June and July in two geographically different locations in Orange County -- and has linked those to samples from Jerusalem, in Israel, and recent samples from London, England
  • The Rockland County case was an unvaccinated patient who had a vaccine-derived strain of the virus that indicates it would have been contracted by someone who got a live dose used by a country outside the US; in rare instances, people given the live virus can spread it to other people who haven’t been vaccinated.

The CDC has detected more polio virus in more Hudson Valley wastewater samples, now in a different New York county -- and state health officials are now warning that the latest environmental evidence "further indicates potential community spread" of a childhood disease that the United States declared eradicated more than four decades ago.

The state health department, which launched wastewater surveillance earlier this month after officials announced the first confirmed U.S. polio case in nearly a decade in an unvaccinated patient in Rockland County on July 21, says the CDC confirmed its presence in Orange County samples as well. Those samples were taken from June and July in two geographically different locations, officials said.

While there are no active confirmed polio cases in Orange County, according to the local county executive, it has a much lower polio vaccination rate (59.45%) among 2-year-olds than the state average (79.1%), which makes the community vulnerable.

New York health officials sought to underscore the point in a Thursday statement.

"These environmental findings—which further indicate potential community spread—in addition to the paralytic polio case identified among a Rockland County resident, underscore the urgency of every New York adult and child getting immunized against polio, especially those in the greater New York metropolitan area," it said.

Health officials say the samples from the confirmed Rockland County case appear genetically linked to two collected from the early June samples from Rockland County and samples from greater Jerusalem, Israel, as well as to the recently-detected environmental samples in London. The Rockland County resident had no known travel to London, officials said.

https://www.nbcnewyork.com/news/local/ny-latest-cdc-findings-indicate-potential-community-spread-of-polio-in-hudson-valley/3809605/